期刊
DRUG RESISTANCE UPDATES
卷 27, 期 -, 页码 39-58出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2016.06.003
关键词
Precision medicine; Polymeric nanoparticles; Theranostics; Molecular imaging; Fluorescence real-time imaging; Image-guided surgery
资金
- European Research Council under the European Union's Seventh Framework Programme (FP)/ERC [[617445]- PolyDorm]
- Israel Science Foundation [918/14]
- Israeli National Nano technology Initiative (INNI)
- Focal Technology Area (FTA) program: Nanomedicine for Personalized Theranostics
- Leona M. and Harry B. Helmsley Nanotechnology Research
- Marian Gertner Institute for Medical Nanosystems
- Tel Aviv University Center for Nanoscience and Nanotechnology
The progress in medical research has led to the understanding that cancer is a large group of heterogeneous diseases, with high variability between and within individuals. This variability sprouted the ambitious goal to improve therapeutic outcomes, while minimizing drug adverse effects through stratification of patients by the differences in their disease markers, in a personalized manner, as opposed to the strategy of one therapy fits all. Nanotheranostics, composed of nanoparticles (NPs) carrying therapeutic and/or diagnostics probes, have the potential to revolutionize personalized medicine. There are different modalities to combine these two distinct fields into one system for a synergistic outcome. The addition of a nanocarrier to a theranostic system holds great promise. Nanocarriers possess high surface area, enabling sophisticated functionalization with imaging agents, thus gaining enhanced diagnostic ability in real-time. Yet, most of the FDA-approved theranostic approaches are based on small molecules. The theranostic approaches that are reviewed herein are paving the road towards personalized medicine through all stages of patient care: starting from screening and diagnostics, proceeding to treatment and ending with treatment follow-up. Our current review provides a broad background and highlights new insights for the rational design of theranostic nanosystems for desired therapeutic niches, while summoning the hurdles on their way to become first-line diagnostics and therapeutics for cancer patients. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据